Cell Therapy Technologies Market

Product Launches & Acquisitions-Major Growth Strategies Adopted by Key Players in the Cell Therapy Instruments Market

The cell therapy instruments market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4%. Cell therapy instruments find major applications in regenerative medicine, stem cell research, cancer research, and cell biology research. These instruments are also extensively used in research centers and research institutes for life science and biopharmaceutical R&D. Rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are the key factors driving the growth of this market.

The cell therapy instruments market is dominated by players such as Beckman Coulter, Inc. (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (US), and Thermo Fisher Scientific, Inc. (US). Product launches and acquisitions are the key growth strategies followed by most players in this market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US)

Thermo Fisher was the largest player in the cell therapy instruments market in 2017. In order to maintain its position in the market and further expand its product portfolio, the company has been focusing on the strategies of product launches, acquisitions, and expansions. For instance, in February 2017, the company acquired Finesse Solutions (US), which helped it to increase and expand its cell therapy instruments portfolio. In February 2018, the company launched an advanced laboratory management system for data integrity and complete regulatory compliance.

Merck KGaA (Germany)

Merck ranked second in the cell therapy instruments market in 2017. The company offers a strong life sciences product portfolio. To further enhance its market position, the company focuses on the strategies of collaborations, agreements, and acquisitions. In November 2015, Merck acquired Sigma-Aldrich Corporation (US) for USD 17 billion. This acquisition enabled the company to expand its share in the life sciences industry. The company has also entered into various agreements and collaborations to increase its R&D activities and supply products to a number of companies and laboratories. Moreover, in February 2018, Merck invested in the Asian region in order to build a robust manufacturing and distribution platform over a span of two years.

Related Reports:

Cell Therapy Technologies Market by Product (Consumables, Equipment, Software), Cell Type (Human Stem & Differentiated, Animal), Process Stages (Cell Processing, Distribution, Handling, QC), End User, and Region - Global Forecast to 2023

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
BT 6823
Published ON
Dec, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cell Therapy Technologies Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved